Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma

BACKGROUND. Relapsed or refractory mantle cell lymphoma (MCL) has a poor prognosis. The best outcome is achieved in patients who have a partial or complete response to salvage treatment and proceed to allogeneic stem cell transplant. PATIENTS AND METHODS. Twenty‐one patients were given a combination...

Full description

Saved in:
Bibliographic Details
Published in:Oncologist
Main Authors: Lee, Hun Ju, Romaguera, Jorge E., Feng, Lei, Desai, Aakash P., Zhang, Liang, Fanale, Michelle, Samaniego, Felipe, Hagemeister, Fredrick B., Fayad, Luis E., Rodriguez, Maria A., Medeiros, Jeffrey L., Hartig, Kimberly, Nomie, Krystle, Ahmed, Makhdum, Badillo, Maria, Ye, Haige, Oki, Yasuhiro, Lin, Pei, Nastoupil, Loretta, Westin, Jason, Wang, Michael
Format: Artigo
Language:Inglês
Published: AlphaMed Press 2017
Subjects:
Hematologic Malignancies
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5423503/
https://ncbi.nlm.nih.gov/pubmed/28408615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0328
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items